[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100635794":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":19,"responsibleParty":30,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":38,"acronym":10,"eligibilityCriteria":39,"healthyVolunteers":36,"sex":40,"minAge":41,"maxAge":10,"enrollmentInfo":42,"targetDuration":10,"studyType":45,"phases":10,"briefSummary":46,"conditions":47,"keywords":50,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Sohag University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Group 1",null,"patients with locally advanced rectal adenocarcinoma received total neoadjuvant therapy then underwent total mesorectal excision.",[13],{"name":14,"role":15,"phone":16,"phoneExt":17,"email":18},"Manar Abd El-Mawla Mohamed, master","CONTACT","01114314946","002","Manar.Abdelmola@med.sohag.edu.eg",[20],{"facility":5,"status":10,"city":21,"state":10,"zip":10,"country":22,"countryCode":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":10},"Sohag","Egypt","EG",{"type":25,"coordinates":26},"Point",[27,28],31.69478,26.55695,{"lat":28,"lon":27},{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Manar Abdelmola Mohamed","Resident doctor at Department of Clinical Oncology and Nuclear Medicine, Sohag Faculty of Medicine","100635794","nodal-downstaging-versus-primary-tumor-regression-as-predictors-of-survival-after-total-neoadjuvant-therapy-for-rectal-cancer-a-retrospective-study-100635794",false,"NCT07557316","Nodal Downstaging Versus Primary Tumor Regression as Predictors of Survival After Total Neoadjuvant Therapy for Rectal Cancer: A Retrospective Study","Inclusion Criteria:\n\npatients who were more than18 years old at time of diagnosis. Pathological confirmation of rectal adenocarcinoma. Locally advanced stage II\\&III rectal carcinoma (≥T3 and or N+) at initial diagnosis.\n\nPatients treated with Total Neoadjuvant Therapy (TNT), including either chemoradiotherapy (CRT) followed by consolidation chemotherapy, induction chemotherapy followed by CRT, or short-course radiotherapy (SCRT) followed by chemotherapy, and subsequently undergoing TME.\n\nAvailable pathological assessment of surgical specimens.\n\nExclusion Criteria:\n\nPatients with distant metastasis at presentation or other comorbid diseases. Patients with incomplete clinical and pathological staging information. Missing key clinical or pathological data. Patients who did not receive TNT or undergo TME surgery.","ALL","18 Years",{"count":43,"type":44},100,"ESTIMATED","OBSERVATIONAL","To evaluate the prognostic impact of post-TNT pathological nodal status (ypN) on LRFS, DMFS, and OS, and compare it with that of primary tumor response",[48,49],"Rectal Cancer Patients","Total Neoadjuvant Therapy",[51,52,53],"ypN","TNT","ypT","NOT_YET_RECRUITING","2026-04-22",{"date":57,"type":58},"2026-04-29","ACTUAL",{"date":60,"type":44},"2026-05-10",{"date":62,"type":44},"2027-05-10",{"name":5,"class":6},1]